A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of CAN008 Plus TMZ During and After Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma
Latest Information Update: 10 Jul 2023
At a glance
- Drugs Asunercept (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors CANbridge Pharmaceuticals
- 03 Jul 2023 According to a CANbridge Pharmaceuticals media release, based on the interim analysis recommendation of the independent data monitoring committee, the company plans to continue the ongoing Phase 2 study of CAN008 in patients with newly diagnosed glioblastoma multiforme (GBM) in China to completion.
- 28 Mar 2023 Status changed from recruiting to active, no longer recruiting as per CANbridge Pharmaceuticals media release
- 17 Mar 2023 According to a CANbridge Pharmaceuticals media release, an interim data analysis is expected in mid-2023.